Drug Profile
Nafithromycin - Wockhardt
Alternative Names: WCK 4873Latest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator Wockhardt
- Class Antibacterials; Hexoses; Ketolides; Lactones; Macrolides; Pyridines; Thiadiazoles
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Community-acquired pneumonia
- No development reported Haemophilus infections
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for preclinical development in Haemophilus-infections in India (PO)
- 11 Nov 2019 Wockhardt plans a phase III trial for Community-acquired pneumonia in India (PO) (CTRI/2019/11/021964)
- 28 Oct 2019 No recent reports of development identified for phase-I development in Community-acquired-pneumonia(In volunteers) in USA (IV)